Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from STAT

10:11 EST 24th November 2017 | BioPortfolio

Here are the most relevant search results for "STAT" found in our extensive news archives from over 250 global news sources.

More Information about STAT on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about STAT for you to read. Along with our medical data and news we also list STAT Clinical Trials, which are updated daily. BioPortfolio also has a large database of STAT Companies for you to search.

Showing News Articles 1–25 of 2,500+ from STAT

Friday 24th November 2017

STAT Plus: Pharmalittle: Teva plots major layoffs; Bayer defends its ‘pipeline problem’

Teva is on the brink of major layoffs, and the plan is to let go of more than 1,500 employees in Israel and another 1,000 or so more in the…

Opinion: Relaxing patient privacy rules would worsen the opioid epidemic

Loosening 42 CFR Part 2, a vital privacy protection rule for people in treatment for a substance use disorder, would undermine efforts to solve the nation's opioid crisis.

Match matters: Here’s some advice on how to interview for your residency

Where we match can have a profound impact on our lives, and on the communities where we learn. Here are some tips on how to find that best fit.

I’m a second-year resident. Here’s some advice on how to interview for your residency

Where we match can have a profound impact on our lives, and on the communities where we learn. Here are some tips on how to find that best fit.

A holiday gift guide for all the science lovers on your list

We've taken some of the work out of the holiday by rounding up the most inspired, innovative, and delightful gift ideas for anyone on your list.

A holiday gift guide for all the science-lovers on your list

We've taken some of the work out of the holiday by rounding up the most inspired, innovative, and delightful gift ideas for anyone on your list.

STAT Plus: C-Suite: A mother, different cultures, and Gen. Patton all influence leadership styles

Each month, we turn to a new panel of biopharma executives for insights about leadership and management — and thriving in a roller-coaster industry.

Wednesday 22nd November 2017

STAT Plus: FDA issues final guidelines for generic abuse-deterrent opioids

The agency hopes to mitigate the extent to which individuals misuse opioids while simultaneously lowering prescription drug costs.

Opinion: In a land of plenty, a food bank and a health insurer team up to take on food insecurity

A South Florida food bank and a health insurer are studying if giving healthy food to people with food insecurity can improve their health and reduce their health care costs.

STAT Plus: Pharmalittle: FDA pursues pharmacies that help internet orders; will Vioxx return?

The FDA sent criminal investigation agents with search warrants into stores in Florida that help customers order drugs from pharmacies in Canada.

These bacteria keep swapping resistance genes, even with no antibiotics around

If we reduce antibiotic use, we could reduce the resistance that’s been naturally selected for over time. But new research finds that isn’t always the case.

Bacteria swap DNA that spreads antibiotic resistance

If we reduce antibiotic use, we could reduce the resistance that’s been naturally selected for over time. But new research finds that isn’t always the case.

A scrappy upstart in the pain pill business takes on mighty Purdue Pharma

Collegium, which makes abuse-deterrent opioids, convinced top health insurers to cover only its product Xtampza — and not Purdue's infamous OxyContin.

Opinion: Football-related injuries extend far beyond concussions

In football, concussions matter. But other injuries that make it difficult to walk or cause chronic pain are also high prices to pay for playing the game.

STAT Plus: What will FDA’s new rules mean for legitimate stem cell treatments?

BlueRock Therapeutics executives weigh in on new Food and Drug Administration guidelines for investigative stem cell therapies.

Tuesday 21st November 2017

STAT Plus: Not a Dutch treat: Drug prices prompt debate over ‘last resort’ options in Amsterdam

The government is about to debate pharmaceutical policies, but the session may be hijacked by concerns over prices and the overall influence of drug makers.

Nearly half of U.S. cancer deaths blamed on unhealthy behavior

A new study finds that 45 percent of cancer deaths and 42 percent of diagnosed cancer cases could be attributed to "modifiable" risk factors.

Self-harm, suicide attempts climb among U.S. girls, study says

Attempted suicides, drug overdoses, cutting and other types of self-injury have increased substantially in U.S. girls, a 15-year study found.

Startup seeking to resurrect Vioxx, arthritis drug pulled from market

Merck & Co. voluntarily pulled the blockbuster drug in 2004 amid evidence that it doubled the chances of having a heart attack or stroke.

STAT Plus: Pharmalittle: U.K. cries foul on price hikes; Roche sues Pfizer over a biosimilar

Canadian drug firm Concordia has raised the price of a thyroid drug by about 6,000 percent over the past decade.

Before heading offshore, herpes researcher experimented on people in U.S. hotel rooms

William Halford met people with herpes in hotel rooms near his laboratory, and injected them with a experimental herpes vaccine.

STAT Plus: Effective treatments for ALS remain elusive after key clinical trial fails

An experimental ALS drug failed to improve symptoms in a large clinical trial. It was a blow to Cytokinetics, the biotech developing the drug.

Opinion: Cutting the orphan drug tax credit would take away my day in the sun

Eliminating the tax incentive for making orphan drugs would slow the creation of new ones, making the outlook even more bleak for people with rare diseases.

A defiant country doctor fights for her license and a disappearing style of medicine

A New Hampshire doctor fighting to regain her license has become a symbol of a kind of physician autonomy that is almost extinct.

STAT Plus: Our bodies are full of bugs. This MIT engineer wants to manipulate them to treat disease

For all our talk of microbiomes, we aren’t all that great at shaping them, says Dr. Timothy Lu of MIT. He’s trying to change that.


Quick Search
Advertisement
 

News Quicklinks